MAWAG
HRTX icon

Mid-American Wealth Advisory Group’s Heron Therapeutics HRTX Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24
Closed -$50 – 159
2025
Q2 		$50 Buy
+24
New +$49 ﹤0.01% 337

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mid-American Wealth Advisory Group's HRTX Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 24 shares — an estimated $50 sold.

Mid-American Wealth Advisory Group first reported a position in HRTX in Q2 2025 and held it in 1 quarter. The position peaked at $50 in Q2 2025. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 24 Heron Therapeutics shares in Q3 2025, an estimated $50.
  • Mid-American Wealth Advisory Group first reported a position in Heron Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Heron Therapeutics position peaked at $50 in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.